{
    "clinical_study": {
        "@rank": "65715", 
        "arm_group": {
            "arm_group_label": "1 Alendronate for 12 months", 
            "arm_group_type": "Experimental", 
            "description": "Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily."
        }, 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the effects of alendronate sodium on skeletal remodeling and bone mineral\n      density of the hip and spine in children with high-turnover idiopathic juvenile\n      osteoporosis."
        }, 
        "brief_title": "Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.", 
                        "title": "Alendronate"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "10"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "10"
                                            }
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@spread": "2.3", 
                                                "@value": "9.4"
                                            }
                                        }, 
                                        "sub_title": "Pre-Treatment (Baseline)"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@spread": "2.3", 
                                                "@value": "10.6"
                                            }
                                        }, 
                                        "sub_title": "Post Treatment"
                                    }
                                ]
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "5"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "5"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "10"
                                        }
                                    }, 
                                    "sub_title": "United States"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "Agreement with Merck: to submit a copy of any proposed abstract, manuscript and/or press release to Merck for review and comment at least 30 days prior to submission for publication or presentation."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Number of participants with increase in bone mineral density at Lumbar Spine and/or Hip at 12 months as compared to the bone mineral density at Lumbar Spine and/or Hip obtained before therapy (baseline values)", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.", 
                                "title": "Alendronate"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "0.11", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Number of participants with increase in bone mineral density at Lumbar Spine and/or Hip at 12 months as compared to the bone mineral density at Lumbar Spine and/or Hip obtained before therapy (baseline values)", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Increased Bone Mineral Density", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "per protocol", 
                        "safety_issue": "No", 
                        "time_frame": "at 12 months", 
                        "title": "Number of Participants With Increased Bone Mineral Density", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Participants (pts) with fractures bef.and aft.therapy; pts analysed for  average changes in mineral apposition rate (MAR) (high (1.9um/day) to near normal (1.2 um/day)as revealed in bone biopsies. MAR is the distance between the two tetracycline labels (um/day). The data represent the average of 10-17 measurements of the disltance obtained by reading 2-7 individual slides of bone biopsy and pts analysed for average insignificant biochemical markers (serum bone specific alkaline phosphatase for bone formation and urinary N-telopeptide for resorption)to determine the effect of therapy.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.", 
                                "title": "Alendronate"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "9"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "9"
                                                    }
                                                }, 
                                                "sub_title": "Participants with fractures before therapy."
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Participants with fractures after therapy."
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "9"
                                                    }
                                                }, 
                                                "sub_title": "Pts average MAR near normal after therapy"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "9"
                                                    }
                                                }, 
                                                "sub_title": "Pts av biomarker change insignificant aft. therapy"
                                            }
                                        ]
                                    }, 
                                    "description": "Participants (pts) with fractures bef.and aft.therapy; pts analysed for  average changes in mineral apposition rate (MAR) (high (1.9um/day) to near normal (1.2 um/day)as revealed in bone biopsies. MAR is the distance between the two tetracycline labels (um/day). The data represent the average of 10-17 measurements of the disltance obtained by reading 2-7 individual slides of bone biopsy and pts analysed for average insignificant biochemical markers (serum bone specific alkaline phosphatase for bone formation and urinary N-telopeptide for resorption)to determine the effect of therapy.", 
                                    "param": "Number", 
                                    "title": "Participants (1) With Fractures Before and After Therapy,(2)Analysed for Average Changes From High to Near Normal Mineral Apposition Rate (MAR) After Therapy,(3)Analysed for Average Insignificant Changes in Biochemical Markers After Therapy.", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Per protocol", 
                        "safety_issue": "Yes", 
                        "time_frame": "Before and 12 months after treatment with alendronate", 
                        "title": "Participants (1) With Fractures Before and After Therapy,(2)Analysed for Average Changes From High to Near Normal Mineral Apposition Rate (MAR) After Therapy,(3)Analysed for Average Insignificant Changes in Biochemical Markers After Therapy.", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.", 
                        "title": "Alendronate"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "10", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "10", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "6 Months"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "10", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "recruitment_details": "Dates of the recruitment period: 5/3/2001 to 7/23/2002. Types of location: Out-patient clinic, Clinical and Translational Research Center (CTRC, formerly General Clinical Research Center), Medical University of South Carolina."
            }, 
            "point_of_contact": {
                "email": "bowlbyd@musc.edu", 
                "name_or_title": "Deborah A Bowlby, M.D., Assistant Professor, Pediatric Endocrinology", 
                "organization": "Medical University of South Carolina", 
                "phone": "843-792-6807 ext NA"
            }
        }, 
        "completion_date": {
            "#text": "November 2008", 
            "@type": "Actual"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive oral alendronate sodium weekly for 1 year.  Treatment continues in the\n      absence of disease progression or unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Eligibility Criteria:\n\n          -  5-14 years of age\n\n          -  Weight 20 kg or greater\n\n          -  History of one or more atraumatic fracture\n\n          -  Sexual development no greater than Tanner II\n\n          -  Osteoporosis by DXA (Diagnosis of high-turnover osteoporosis with no underlying cause\n             (e.g., malignancy, hyperthyroidism, hyperparathyroidism, or vitamin D intoxication)\n\n        Inclusion Criteria:\n\n          -  Male and female children with a history of one or more atraumatic fractures, or\n             evidence of one or more compression fractures on radiographs of the spine (reduction\n             of >20%).\n\n          -  Bone mineral density by DXA at 2 standard deviations (SD) below normal mean for age\n             (Z-score at least 2 SD below normal mean at the lumbar spine or hip)\n\n          -  Parental consent (and patient assent after age 12 years) to participate in the study.\n\n          -  Sexual development at Tanner stage II or less (Prepubertal stage)\n\n          -  Weight 20kg and more\n\n        Exclusion Criteria:\n\n          -  History of severe gastritis or reflux\n\n          -  Marked kyphoscoliosis or inability to sit or stand for at least 30 minutes.\n\n          -  Abnormalities of the esophagus that delay emptying (e.g., strictures or achalasia)\n\n          -  Hypersensitivity to bisphosphonates\n\n          -  Uncorrected hypocalcemia\n\n          -  History of gastric or duodenal ulcers\n\n          -  Renal dysfunction as indicated by serum Creatinine greater than 1.5 mg/dL\n\n          -  Liver dysfunction as indicated by serum SGPT greater than 2 times upper limit of\n             normal for age or serum total bilirubin greater than 2.0 mg/dL\n\n          -  Diagnosis of osteogenesis imperfecta (including family history) or blue sclerae or\n             deafness\n\n          -  Diagnosis of active rickets, osteomalacia, or bone alkaline phosphatase > 2 times\n             normal for age\n\n          -  Severe gastritis or reflux\n\n          -  Pregnancy\n\n          -  Anorexia Nervosa\n\n               -  Prior/Concurrent Therapy\u2014\n\n          -  Prior course of prednisone allowed\n\n          -  No concurrent prednisone except inhaled steroids\n\n          -  No concurrent high-dose glucocorticoids\n\n          -  No concurrent salmon calcitonin\n\n          -  No other concurrent bisphosphonates\n\n          -  No concurrent long-term anti-seizure medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 2, 2001", 
        "firstreceived_results_date": "June 3, 2009", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00010439", 
            "org_study_id": "199/15705", 
            "secondary_id": "FD-R-001847-01"
        }, 
        "intervention": {
            "arm_group_label": "1 Alendronate for 12 months", 
            "description": "Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.", 
            "intervention_name": "Alendronate", 
            "intervention_type": "Drug", 
            "other_name": "Fosamax"
        }, 
        "intervention_browse": {
            "mesh_term": "Alendronate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "arthritis & connective tissue diseases", 
            "idiopathic juvenile osteoporosis", 
            "rare disease"
        ], 
        "lastchanged_date": "October 21, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29425"
                }, 
                "name": "Medical University of South Carolina"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Non-Randomized, Open-Label, Prospective, Non-Controlled, 12-Month Clinical Trial to Determine the Effects of Alendronate 35 or 70 mg/Week Depending Upon Body Weight, in Children and Adolescent With IJO", 
        "overall_official": {
            "affiliation": "Medical University of South Carolina", 
            "last_name": "Deborah A Bowlby, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of participants with increase in bone mineral density at Lumbar Spine and/or Hip at 12 months as compared to the bone mineral density at Lumbar Spine and/or Hip obtained before therapy (baseline values)", 
            "measure": "Number of Participants With Increased Bone Mineral Density", 
            "safety_issue": "No", 
            "time_frame": "at 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00010439"
        }, 
        "responsible_party": {
            "name_title": "Deborah A Bowlby, MD., Assistant Professor", 
            "organization": "Medical University of South Carolina"
        }, 
        "results_reference": {
            "citation": "1. Key LL Jr., Ries w, Madyastha P, Reed F: Juvenile Osteoporosis: recognizing the risk. J Pediatr Endocrinol Metab. 2003 May; 16 Suppl 3:683-6, PMID: 12795371 2. P Madyastha, W Ries, B Hollis, F Reed, L Key. Alendronate improved bone mineral density in patients with juvenile osteoporosis. JBMR 20:Suppl 1, page S400, 2005."
        }, 
        "secondary_outcome": {
            "description": "Participants (pts) with fractures bef.and aft.therapy; pts analysed for  average changes in mineral apposition rate (MAR) (high (1.9um/day) to near normal (1.2 um/day)as revealed in bone biopsies. MAR is the distance between the two tetracycline labels (um/day). The data represent the average of 10-17 measurements of the disltance obtained by reading 2-7 individual slides of bone biopsy and pts analysed for average insignificant biochemical markers (serum bone specific alkaline phosphatase for bone formation and urinary N-telopeptide for resorption)to determine the effect of therapy.", 
            "measure": "Participants (1) With Fractures Before and After Therapy,(2)Analysed for Average Changes From High to Near Normal Mineral Apposition Rate (MAR) After Therapy,(3)Analysed for Average Insignificant Changes in Biochemical Markers After Therapy.", 
            "safety_issue": "Yes", 
            "time_frame": "Before and 12 months after treatment with alendronate"
        }, 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2000", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2010"
    }, 
    "geocoordinates": {
        "Medical University of South Carolina": "32.777 -79.931"
    }
}